弥漫性大B细胞淋巴瘤血清生物标志物的研究进展

弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）作为最常见的侵袭性非霍奇金淋巴瘤具有较大的异质性。治疗前期及治疗过程中对患者进行有效的预后评估尤为重要。随着分子基因学及免疫治疗的迅速发展，传统的预后评估手段受到了极大的挑战，综合多种方法对患者进行精准的预后评估至关重要。近年来，多种血清生物标志物在DLBCL的预后评估中受到关注。血清生物标志物以无创、便捷和灵敏度高等优点更易于被患者接受，其在DLBCL预后综合评估中的作用不可忽视。本文就血清生物标志物在DLBCL中的研究进展进行综述。 

Advances in serum biomarkers for diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous and the most common type of invasive non-Hodgkin lymphoma. Therefore, the prognostic evaluation of DLBCL is particularly important for patients before and during the treatment. With the rapid development of molecular biology techniques and immunotherapy, the traditional prognostic assessment methods have been greatly challenged. Considerable attention has been paid toward the accurate prognostic evaluation of patients using multiple methods. Various serum biomarkers have been recently implicated in the prognostic evaluation of DLBCL. Serum biomarkers are non-invasive, convenient, and highly sensitive, and the tests for serum biomarkers are more easily acceptable to patients. Therefore, the role of serum biomarkers in the comprehensive evaluation of DLBCL prognosis cannot be ignored. This article reviews the research progress on serum biomarkers for the prognostic evaluation of DLBCL.